Dr. Beal Essink, Principal Investigator at Summit Research, a Headlands Research site, contributed to the landmark SURMOUNT-1 trial, now reporting 3-year outcomes.
This 3-year study found that adults with obesity and prediabetes who were treated with tirzepatide experienced sustained weight reductions of up to 19.7%, and markedly lower risk of developing type 2 diabetes (1.3% vs. 13.3% with placebo).
These findings reinforce tirzepatide’s potential to not only support meaningful, long-term weight loss but also to significantly delay or prevent the onset of type 2 diabetes.
Read more in The New England Journal of Medicine.